Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases

治疗性肽持续脉络膜上递送治疗眼部疾病

基本信息

批准号：
9317491
负责人：
Peter A Campochiaro
金额：
$ 20.44万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2019-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9317491
关键词：
Affect Age Animal Disease Models Animal Model Blindness Blood Vessels Choroidal Neovascularization Complications of Diabetes Mellitus Computer Simulation Computing Methodologies Convection Development Diabetic Retinopathy Diffuse Diffusion Dimensions Disadvantaged Disease Drug Delivery Systems Edema Evaluation Extravasation Exudative age-related macular degeneration Eye Feedback Frequencies Goals Growth Factor Human In Situ Injectable Injection of therapeutic agent Label Laboratories Liquid substance Measures Medical Modeling Mus New Agents Oryctolagus cuniculus Patients Peptide Transport Peptides Permeability Pharmaceutical Preparations Physiological Plasma Preparation Proteins Reaction Regimen Research Proposals Retina Retinal Neovascularization Retinal Vein Occlusion Schedule Testing Therapeutic Time Tissues Vascular Endothelial Growth Factors Vascular Permeabilities Visual impairment angiogenesis comparative efficacy design experimental study improved in vivo intravitreal injection macula macular edema multidisciplinary neovascularization particle peptide drug pre-clinical prevent retina blood vessel structure simulation

项目摘要

Summary: Current therapies for neo-vascular age-related macular degeneration and macular edema are injected directly into the vitreous on a monthly or bi-monthly schedule. There is a great need for new agents with improved efficacy as well as other modes of delivery for less frequent administration. We have developed peptides with potent activity in animal models of these diseases as well as sustained delivery vehicles which are able to release the peptides in a controlled manner for multiple months. Here we propose to test the hypothesis that our sustained delivery drug can be injected successfully into the suprachoridal space behind the retina from which the active peptides will be released into the affected tissues to inhibit neovascularization and edema. Computational modeling will be used to quantify the drug delivery and extend it to a model of the human eye. The proposal is multidisciplinary and is greatly strengthened by the team's expertise in animal models, particle design and fabrication, peptide development, and computational methods.

概括：目前针对新生血管性年龄相关性黄斑变性和黄斑水肿的治疗方法是按每月或每两个月的计划直接注射到玻璃体中。非常需要具有改进功效的新药物以及其他给药方式，频率较低行政。我们开发了在这些动物模型中具有有效活性的肽疾病以及能够释放肽的持续递送载体控制方式长达数月。在这里，我们建议检验我们的假设持续递送药物可以成功地注射到后面的脉络膜上腔视网膜，活性肽将被释放到受影响的组织中以抑制新血管形成和水肿。计算模型将用于量化药物交付并将其扩展到人眼模型。该提案是多学科的，该团队在动物模型、颗粒设计和制造方面的专业知识大大加强了，肽开发和计算方法。